Cancer and graft-versus-host disease therapy developer MaaT has raised a second tranche to hike the Biocodex-backed round to $30.4m.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

GV was among the participants in the healthcare management platform developer's third round this year, valuing it at $1.5bn.

The diabetes treatment developer, which counts Tasly and Legend Star among its investors, has received what it referred to as pre-IPO funding.

The $59.4m round will support the development of four clinical-stage candidates for neurological disorders Noema licensed from shareholder Roche.

The gene-editing drug developer has completed its first publicly announced round, with Alphabet unit GV the only disclosed participant.

The Croda International-backed biopharmaceutical developer has cloesd a $13.2m round to boost its overall funding to about $25m.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Existing backers including Draper Esprit and Sussex Place Ventures have reinvested to bring Endomag’s overall funding to above $43m.

The immuno-ocology startup has completed a series A round backed by Merck & Co investment vehicle MRL Ventures Fund.